X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (40411) 40411
Book Chapter (373) 373
Magazine Article (174) 174
Newsletter (82) 82
Newspaper Article (47) 47
Book / eBook (35) 35
Dissertation (21) 21
Publication (13) 13
Web Resource (10) 10
Conference Proceeding (7) 7
Reference (6) 6
Book Review (3) 3
Paper (2) 2
Government Document (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32726) 32726
female (18461) 18461
male (17008) 17008
middle aged (13155) 13155
adult (11461) 11461
aged (10250) 10250
venous thromboembolism (10203) 10203
thrombosis (9411) 9411
risk factors (9247) 9247
peripheral vascular disease (8385) 8385
venous thrombosis (7953) 7953
hematology (7801) 7801
thromboembolism (7495) 7495
anticoagulants - therapeutic use (7196) 7196
treatment outcome (6454) 6454
surgery (6421) 6421
prevention (4959) 4959
deep-vein thrombosis (4931) 4931
anticoagulants (4841) 4841
retrospective studies (4743) 4743
venous thrombosis - etiology (4655) 4655
venous thrombosis - drug therapy (4327) 4327
pulmonary embolism (4296) 4296
aged, 80 and over (4162) 4162
risk (4096) 4096
medicine, general & internal (3642) 3642
adolescent (3640) 3640
pulmonary-embolism (3372) 3372
care and treatment (3345) 3345
medicine & public health (3345) 3345
diagnosis (3323) 3323
molecular-weight heparin (3117) 3117
management (3020) 3020
venous thrombosis - diagnosis (2945) 2945
therapy (2887) 2887
anticoagulants - administration & dosage (2848) 2848
time factors (2841) 2841
risk-factors (2820) 2820
prospective studies (2737) 2737
cancer (2735) 2735
complications (2719) 2719
venous thrombosis - prevention & control (2718) 2718
deep venous thrombosis (2696) 2696
venous thrombosis - therapy (2580) 2580
young adult (2509) 2509
heparin (2471) 2471
health aspects (2444) 2444
incidence (2408) 2408
follow-up studies (2402) 2402
anticoagulants - adverse effects (2400) 2400
venous thromboembolism - prevention & control (2339) 2339
risk assessment (2335) 2335
oncology (2276) 2276
warfarin (2258) 2258
analysis (2240) 2240
prophylaxis (2221) 2221
recurrence (2217) 2217
deep vein thrombosis (2214) 2214
venous thrombosis - complications (2188) 2188
venous thrombosis - diagnostic imaging (2159) 2159
mortality (2123) 2123
child (2122) 2122
cardiac & cardiovascular systems (2110) 2110
patients (2090) 2090
research (2090) 2090
pregnancy (2030) 2030
abridged index medicus (1951) 1951
drug therapy (1933) 1933
catheterization, central venous - adverse effects (1925) 1925
heparin, low-molecular-weight - therapeutic use (1920) 1920
anticoagulation (1869) 1869
disease (1835) 1835
blood clot (1789) 1789
prognosis (1782) 1782
venous thromboembolism - etiology (1776) 1776
venous thrombosis - epidemiology (1768) 1768
tomography, x-ray computed (1766) 1766
heparin - therapeutic use (1718) 1718
radiology, nuclear medicine & medical imaging (1690) 1690
venous thromboembolism - drug therapy (1680) 1680
fibrinolytic agents - therapeutic use (1666) 1666
animals (1658) 1658
health risk assessment (1642) 1642
pediatrics (1582) 1582
pulmonary embolism - etiology (1549) 1549
clinical neurology (1547) 1547
pharmacology & pharmacy (1509) 1509
stroke (1422) 1422
children (1419) 1419
pulmonary embolism - prevention & control (1415) 1415
venous thromboembolism - epidemiology (1404) 1404
thromboprophylaxis (1401) 1401
enoxaparin (1391) 1391
hemorrhage - chemically induced (1376) 1376
ultrasonography (1372) 1372
administration, oral (1364) 1364
thrombosis - etiology (1364) 1364
thrombolytic therapy (1363) 1363
internal medicine (1354) 1354
cohort studies (1335) 1335
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38815) 38815
German (858) 858
French (779) 779
Spanish (314) 314
Japanese (288) 288
Russian (172) 172
Chinese (169) 169
Portuguese (114) 114
Italian (108) 108
Polish (83) 83
Korean (49) 49
Czech (46) 46
Danish (41) 41
Turkish (37) 37
Dutch (32) 32
Hungarian (31) 31
Norwegian (29) 29
Swedish (27) 27
Finnish (22) 22
Croatian (12) 12
Hebrew (11) 11
Romanian (11) 11
Serbian (10) 10
Bulgarian (8) 8
Ukrainian (6) 6
Slovak (5) 5
Bosnian (4) 4
Slovenian (3) 3
Icelandic (2) 2
Lithuanian (2) 2
Persian (2) 2
Arabic (1) 1
Estonian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e44S - e88S
Background: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant... 
GAMMA-CARBOXYGLUTAMIC ACID | INTRAVENOUS PHYTONADIONE VITAMIN-K-1 | FACTOR-XA INHIBITOR | VENOUS LIMB GANGRENE | EUROPEAN CONCERTED ACTION | LOW-INTENSITY WARFARIN | RESPIRATORY SYSTEM | VITAMIN-K ANTAGONISTS | TOTAL HIP-REPLACEMENT | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | United States | Humans | Pyridines - pharmacokinetics | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacokinetics | Dose-Response Relationship, Drug | Rivaroxaban | Pyridines - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Benzimidazoles - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Morpholines - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Evidence-Based Medicine | Factor Xa - metabolism | Thiophenes - pharmacokinetics | Vitamin K - blood | Antithrombins - adverse effects | Anticoagulants - pharmacokinetics | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e419S - e496S
... (PE), we recommend initial parenteral anticoagulant therapy (Grade 1B) or anticoagulation with rivaroxaban... 
RIGHT-VENTRICULAR DYSFUNCTION | RECURRENT VENOUS THROMBOEMBOLISM | TISSUE-PLASMINOGEN-ACTIVATOR | RESPIRATORY SYSTEM | ACUTE PULMONARY-EMBOLISM | MOLECULAR-WEIGHT HEPARIN | VENA-CAVA FILTER | ORAL ANTICOAGULANT-THERAPY | INTRAVENOUS UNFRACTIONATED HEPARIN | LONG-TERM TREATMENT | DEEP-VEIN-THROMBOSIS | CRITICAL CARE MEDICINE | Venous Thrombosis - diagnosis | Pulmonary Embolism - prevention & control | United States | Humans | Venous Thrombosis - blood | Heparin, Low-Molecular-Weight - adverse effects | Hemorrhage - prevention & control | Long-Term Care | Heparin, Low-Molecular-Weight - therapeutic use | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - prevention & control | Polysaccharides - therapeutic use | Drug Administration Schedule | Venous Thrombosis - drug therapy | Administration, Oral | Risk Factors | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Pulmonary Embolism - blood | International Normalized Ratio | Diagnostic Imaging | Pulmonary Embolism - diagnosis | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Journal Article
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e152S - e184S
...: The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines... 
COMPUTERIZED DECISION-SUPPORT | INTENSITY WARFARIN THERAPY | DEFINITE ANTIPHOSPHOLIPID SYNDROME | RESPIRATORY SYSTEM | PROTHROMBIN COMPLEX CONCENTRATE | MOLECULAR-WEIGHT HEPARIN | DEEP-VEIN THROMBOSIS | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | ACUTE VENOUS THROMBOEMBOLISM | ORAL VITAMIN-K | CRITICAL CARE MEDICINE | United States | Humans | Decision Support Systems, Clinical | Heparin - therapeutic use | Hemorrhage - prevention & control | Long-Term Care | Heparin - adverse effects | Heparin - pharmacokinetics | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Drug Interactions | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions | Fibrinolytic Agents - therapeutic use | Thrombosis - blood | Thrombosis - prevention & control | Patient Education as Topic | Polysaccharides - therapeutic use | Drug Administration Schedule | Administration, Oral | Hemorrhage - therapy | Polysaccharides - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | International Normalized Ratio | Thrombosis - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Self Care | Polysaccharides - pharmacokinetics | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH),... 
RESPIRATORY SYSTEM | LOW-MOLECULAR-WEIGHT | ACUTE MYOCARDIAL-INFARCTION | DEEP-VEIN THROMBOSIS | HEPARIN-INDUCED THROMBOCYTOPENIA | RECOMBINANT FACTOR VIIA | PATHOLOGISTS CONFERENCE XXXI | PARTIAL THROMBOPLASTIN TIME | ANTI-FACTOR-XA | ACUTE VENOUS THROMBOEMBOLISM | UNFRACTIONATED HEPARIN | CRITICAL CARE MEDICINE | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e351S - e418S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e601S - e636S
Objectives: This article provides recommendations on the use of antithrombotic therapy in patients with stroke or transient ischemic attack (TIA). Methods... 
HIGH-RISK PATIENTS | TISSUE-PLASMINOGEN ACTIVATOR | CEREBRAL VENOUS THROMBOSIS | PATENT FORAMEN OVALE | RESPIRATORY SYSTEM | LONG-TERM SURVIVAL | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | ASPIRIN PLUS DIPYRIDAMOLE | NONVALVULAR ATRIAL-FIBRILLATION | EXTENDED-RELEASE DIPYRIDAMOLE | CRITICAL CARE MEDICINE | Recombinant Proteins - therapeutic use | United States | Humans | Heparin - therapeutic use | Tissue Plasminogen Activator - therapeutic use | Intracranial Thrombosis - prevention & control | Recombinant Proteins - adverse effects | Heparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ischemic Attack, Transient - etiology | Aspirin - therapeutic use | Intracranial Thrombosis - drug therapy | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Ischemic Attack, Transient - drug therapy | Intermittent Pneumatic Compression Devices | Intracranial Thrombosis - blood | Combined Modality Therapy | Stroke - drug therapy | Evidence-Based Medicine | Stroke - blood | Intracranial Thrombosis - etiology | Thrombolytic Therapy | Ischemic Attack, Transient - blood | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e185S - e194S
Journal Article